Contributors About the editors Preface 1. Computational approaches for anticancer drug design Tha Luong, Grace Persis Burri, Yuvasri Golivi, Ganji Purnachandra Nagaraju, and Bassel F. El-Rayes 1. Introduction 2. Current computational approaches for cancer drug designs 3. Applications of computational approaches in cancer drug designing 4. Challenges and future directions 5. Conclusion References 2.
Molecular modeling approach in cancer drug therapy Bhavini Singh, Rishabh Rege, and Ganji Purnachandra Nagaraju 1. Introduction 2. Drug designing 3. Molecular modeling 4. Methods of molecular modeling 5. Applications of molecular modeling 6. Applications in multidrug-resistant proteins 7. Conclusion References 3.
Discovery of anticancer therapeutics: Computational chemistry and Artificial Intelligence-assisted approach Subrata Das, Anupam Das Talukdar, Deepa Nath, and Manabendra Dutta Choudhury 1. Introduction 2. Drug repurposing 3. Computational chemistry in drug designing 4. Structure-based drug designing 5. ADME/Tox screening and drug-likeness prediction 6. Molecular docking 7. Quantitative structure-activity relationship modeling 8.
Molecular dynamics simulation 9. Artificial Intelligence in drug discovery 10. Conclusion References 4. Artificial intelligence in oncological therapies Shloka Adluru 1. Introduction 2. Importance of early diagnosis 3. How AI can improve accuracy and speed of cancer diagnoses 4. How AI can assess patient background information to determine risk of cancer 5.
Diagnosis of cancer subtype and stage 6. AI in cancer drug discovery and development 7. De novo drug design 8. AI in recommending drug combinations and repurposing drugs 9. AI in identifying drug-target interactions 10. Deep learning, black boxes, and hidden layers 11. Future of AI in oncology 12. Conclusion References 5.
Approach of artificial intelligence in colorectal cancer and in precision medicine Grace Persis Burri, Yuvasri Golivi, Tha Luong, Neha Merchant, and Ganji Purnachandra Nagaraju 1. Introduction 2. Applications of AI in CRC 3. Robotic-assisted surgery 4. Precision medicine in CRC 5. Benefits 6. Limitations 7. Current challenges and prospects 8.
Conclusion Conflict of interest Funding References 6. Artificial intelligence in breast cancer: An opportunity for early diagnosis Rama Rao Malla and Vedavathi Katneni 1. Machine learning 2. Breast cancer 3. Conclusion References 7. Quantitative structure-activity relationship and its application to cancer therapy Bhavini Singh and Rishabh Rege 1. Introduction 2. Function 3.
Origin of QSAR 4. Advanced techniques of QSAR 5. Application in drug design 6. Application in cancer therapy 7. Concerns 8. Conclusion References 8. Structure-based virtual screening strategy for the identification of novel Greatwall kinase inhibitors Anbumani VelmuruganIlavarasi, Tulsi, Saswati Sarita Mohanty, Katike Umamahesh, Amouda Venkatesan, and Dinakara Rao Ampasala 1. Introduction 2.
Computational methods 3. Results and discussion 4. Conclusion Acknowledgments Conflict of interest References 9. Strategies for drug repurposing Aparna Vema and Arunasree M. Kalle 1. Introduction 2. Computational drug repurposing 3. Experimental drug repurposing 4.
Conclusions and perspectives Author contributions Financial disclosures Conflict of interest References 10. Principles of computational drug designing and drug repurposing--An algorithmic approach Angshuman Bagchi 1. Introduction 2. Overview of basic thermodynamic principles involved in computational algorithms 3. Fundamentals of computational algorithms 4. Searching the conformational space 5. Analysis of protein flexibility 6. Drug repurposing 7.
Conclusion Acknowledgment References 11. Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors Asmita Dasgupta, Sanjukta Ghosh, Kastro Kalidass, and Shabnam Farisha 1. Introduction 2. Approved therapeutics for astrocytic tumors 3. Drug discovery approaches against astrocytic tumors 4. Drug discovery for astrocytic tumors by virtual screening 5. Drug repositioning in astrocytic tumor therapy 6. Conclusion Acknowledgments Conflict of interest References 12.
Repurposing of phytocompounds-derived novel bioactive compounds possessing promising anticancer and cancer therapeutic efficacy through molecular docking, MD simulation, and drug-likeness/ADMET studies Rajalakshmi Manikkam, Vijayalakshmi Periyasamy, and Indu Sabapathy 1. Drug repurposing 2. Strategies in drug repurposing 3. Pros and cons of drug repurposing 4. Computational advancements in oncology research 5. Structure-based and target-based virtual screening 6. Systems biology integrated approach in drug repositioning 7. In silico databases and web-based tools for drug repurposing 8.
Phytochemicals repurposed in cancer therapy 9. Antidiabetic phytocompounds repurposed for cancer therapy 10. Conclusion References 13. Old drugs and new opportunities--Drug repurposing in colon cancer prevention Vemula Sarojamma, Manoj Kumar Gupta, Jeelan Basha Shaik, and Ramakrishna Vadde 1. Introduction 2. Principles and tools used in drug repurposing 3. Categories of repurposed drugs against human cancers 4. Drugs used in the treatment of colon cancer 5.
Drug repurposing in the prevention of colon cancer 6. Drug repurposing pitfalls 7. Computational approaches in drug repurposing for colorectal cancer 8. Conclusions and perspectives Conflicts of interest References 14. Repurposing cardiac glycosides as potent immune system modulators in cancer therapy Honey Pavithran, Angelina K. Job, and Ranjith Kumavath 1. Introduction 2. Repurposing cardiac glycosides in cancer treatment 3.
CGs hamper Na+/K+-ATPase signaling complex in cancer 4. Role of the immune system in cancer 5. Conclusions Acknowledgments Consent for publication Ethics approval and consent to participate Conflict of interest References 15. Systems biology tools for the identification of potential drug targets and biological markers effective for cancer therapeutics Gayathri Ashok, P. Priyamvada, Sravan Kumar Miryala, Anand Anbarasu, and Sudha Ramaiah 1. Introduction 2. Current problems in cancer therapies 3. Need for alternative approaches in cancer 4.
GIN: A systems biology approach 5. Types of biological networks 6. Cancer databases 7. Databases for interaction data curation 8. Network construction and visualization 9. Network analysis 10. How can the identified targets be used for cancer therapy? 11. Conclusion Acknowledgments Conflict of interest Authors'' contribution References 16.
Role of human body fluid biomarkers in liver cancer: A systematic review Dahrii Paul, Vigneshwar Suriya Prakash Sinnarasan, Rajesh Das, Dinakara Rao Ampasala, and Amouda Venkatesan 1. Introduction 2. Methods 3. Results 4. Discussion 5. Conclusions References 17. Study on biomarkers in endometrial cancer using transcriptome data: A machine learning approach Dahrii Paul, Vigneshwar Suriya Prakash Sinnarasan, Rajesh Das, Dinakara Rao Ampasala, and Amouda Venkatesan 1. Introduction 2.
Materials and methods 3. Results 4. Discussion 5. Conclusion References 18. Multifaceted functions of PIWI/piRNA complex in cancer and as a therapeutic target for retinoblastoma Rupa Roy, Muthuramalingam Karpagavalli, Athira Ramesh, Jayamuruga Pandian Arunachalam, Sudha Rani Sadras, and Subbulakshmi Chidambaram 1. Introduction 2. Biological functions of PIWI/piRNA in physiological conditions 3. Emerging significance of PIWI/piRNA in various cancers 4.
Retina and its structure 5. Potential role of PIWI and piRNA in RB 6. PIWI/piRNA as future biomarkers in cancer 7. Conclusion Acknowledgments Declaration of competing interest References 19. Emerging role of biosimilars: Focus on Bevacizumab and hepatocellular carcinoma Anum Jalil, James Wert, Akriti Gupta Jain, and Sarfraz Ahmad 1. Introduction 2. Biologics and biosimilars 3. FDA approved biosimilars to date 4.
Role of Bevacizumab and its biosimilar in hepatocellular carcinoma 5. Clinical trials with Bevacizumab and its biosimilar in HCC 6. Conclusions and future perspectives Funding Authors'' contribution References 20. Integrated computational approaches to aid precision medicine for cancer therapy: Present scenario and future prospects Hithesh Kumar, Sravan Kumar Miryala, Anand Anbarasu, and Sudha Ramaiah 1. Introduction 2. Precision cancer medicine: Prospects and hurdles 3. Next generation sequencing and computational genomics in PCM 4. Drug repositioning using translational bioinformatics 5.
Future perspectives 6. Conclusion Acknowledgment Author contributions Declaration of interests References Index.